Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Michael Boe Moeller"'
Autor:
Martine Vornanen, Jan Delabie, Marja-Liisa Karjalainen-Lindsberg, Christer Sundström, Rebecca L. Boddicker, Naoki Oishi, Helle Toldbod, Elisabeth Ralfkiaer, Ivy Luoma, Susanna Mannisto, Michael Boe Moeller, Francesco d'Amore, Esa Jantunen, Birgitta Sander, Peter Noergaard, Fredrik Ellin, Patrick P. Bedroske, James R. Cerhan, N. Nora Bennani, Andrew L. Feldman, Sirpa Leppä, Mats Ehinger, Grete F. Lauritzsen, Rhett P. Ketterling, Stephen Hamilton-Dutoit, Matthew J. Maurer, Knut Liestøl, Thomas Relander, Martin Bjerregård Pedersen, Christopher A. Sattler
Publikováno v:
Blood. 130:822-822
Introduction: Recent results from two independent patient series have shown that chromosomal rearrangements of DUSP22 (DUSP22r+) and TP63 (TP63r+) can predict outcome in ALK-negative anaplastic large cell lymphoma (ALK-ALCL) and peripheral T-cell lym
Autor:
P D Nully Brown, Mette Ø. Pedersen, Michael Boe Moeller, Steen Ingeberg, Leif Spange Mortensen, Lars Møller Pedersen, Bjarne Bach Pedersen, Anne Ortved Gang, C Strøm, Anne Bukh, Ole V. Gadeberg, Francesco d'Amore, Torben Mourits-Andersen, Stanislaw Pulczynski
Publikováno v:
Gang, AO, Stroem, C, Pedersen, M, D'Amore, F A, Pedersen, LM, Bukh, A, Pedersen, BB, Moeller, MB, Mortensen, L S, Gadeberg, O, Ingeberg, S, Mourits-Andersen, T, Pulczynski, S & Brown, P D N 2012, ' R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group. ', Annals of Oncology, vol. 23, no. 1, pp. 147-153 . https://doi.org/10.1093/annonc/mdr058
Gang, A O, Strøm, C, Pedersen, M, d'Amore, F, Pedersen, L M, Bukh, A, Pedersen, B B, Moeller, M B, Mortensen, L S, Gadeberg, O V, Ingeberg, S, Mourits-Andersen, T, Pulczynski, S & Brown, P D N 2012, ' R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group ', Annals of Oncology, vol. 23, no. 1, pp. 147-53 . https://doi.org/10.1093/annonc/mdr058
Gang, A O, Strøm, C, Pedersen, M, d'Amore, F, Pedersen, L M, Bukh, A, Pedersen, B B, Moeller, M B, Mortensen, L S, Gadeberg, O V, Ingeberg, S, Mourits-Andersen, T, Pulczynski, S & Brown, P D N 2012, ' R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group ', Annals of Oncology, vol. 23, no. 1, pp. 147-53 . https://doi.org/10.1093/annonc/mdr058
Background: Optimal treatment of young patients with high-risk diffuse large B-cell lymphoma (DLBCL) remains a matter of debate and requires improvement. The combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHO
Autor:
Maja Ølholm Vase, Bo Amdi Jensen, Paw Jensen, Martin Bjerregaard Pedersen, Charlotte Madsen, Michael Boe Moeller, Knud Bendix, Lars Munksgaard, Peter de Nully Brown, Preben Johansen, Francesco d'Amore, Erik Segel
Publikováno v:
Madsen, C, Pedersen, M B, Vase, M Ø, Segel, E, Bendix, K, Jensen, B A, Jensen, P, Møller, M B, Johansen, P, Munksgaard, L, Brown, P D N & d'Amore, F 2014, ' Clinical Outcome Determinants for Sequentially Transformed Indolent Lymphomas Treated with or without Autologous Stem Cell Transplantation ', ASH Annual Meeting, San Francisco, United States, 06/12/2014-09/12/2014 . < http://www.bloodjournal.org/content/124/21/1194 >
Madsen, C, Pedersen, M B, Vase, M Ø, Segel, E, Bendix, K, Jensen, B A, Jensen, P, Møller, M B, Johansen, P, Munksgaard, L, Brown, P D N & D'Amore, F A 2014, ' Clinical outcome determinats for sequentially transformed indolent lymphomas treated with or without autologous stem cell transplantation ', Blood, vol. 124, no. 21 .
ResearcherID
Madsen, C, Pedersen, M B, Vase, M Ø, Segel, E, Bendix, K, Jensen, B A, Jensen, P, Møller, M B, Johansen, P, Munksgaard, L, Brown, P D N & d'Amore, F 2014, ' Clinical Outcome Determinants for Sequentially Transformed Indolent Lymphomas Treated with or without Autologous Stem Cell Transplantation ', Blood, vol. 124, no. 21 . < http://www.bloodjournal.org/content/124/21/1194 >
Aarhus University
Madsen, C, Pedersen, M B, Vase, M Ø, Segel, E, Bendix, K, Jensen, B A, Jensen, P, Møller, M B, Johansen, P, Munksgaard, L, Brown, P D N & D'Amore, F A 2014, ' Clinical outcome determinats for sequentially transformed indolent lymphomas treated with or without autologous stem cell transplantation ', Blood, vol. 124, no. 21 .
ResearcherID
Madsen, C, Pedersen, M B, Vase, M Ø, Segel, E, Bendix, K, Jensen, B A, Jensen, P, Møller, M B, Johansen, P, Munksgaard, L, Brown, P D N & d'Amore, F 2014, ' Clinical Outcome Determinants for Sequentially Transformed Indolent Lymphomas Treated with or without Autologous Stem Cell Transplantation ', Blood, vol. 124, no. 21 . < http://www.bloodjournal.org/content/124/21/1194 >
Aarhus University
Introduction: When lymphomas originally diagnosed as indolent (IL) transform to a more aggressive histology (TIL) the result is often an accelerated clinical course and a shortened survival. The purpose of this study was (i) to investigate whether au